Home > Insider Trading > Filing (0000899243-22-035333)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1830214	Ginkgo Bioworks Holdings Inc.	DNA	Biological Products, (No Disgnostic Substances) (2836)	872652913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873507	E. Mark Dmytruk	C/O Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue Boston MA 02210	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-10-05	618,242	$0.00	627,344	No	4	M	Direct
Class A Common Stock	Disposition	2022-10-06	279,255	$3.25	348,089	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Restricted Stock Units	Disposition	2022-10-05	618,242	$0.00	0	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,899,021			No	4	M	Direct

Footnotes

Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
On March 14, 2022, the Reporting Person filed a Form 4 that reported RSUs on a consolidated basis with holdings of Class B Common Stock. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports. In addition to the RSUs reported herein, the Reporting Person beneficially owns 658,133 shares of Class B Common Stock, which includes shares of Class B Common Stock that are subject to vesting conditions.